• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Product › Details

antibody-drug conjugate (ADC)

	Next higher product group	cancer drug

Record changed: 2022-07-14

Advertisement

More documents for antibody-drug conjugate (ADC)

• [1] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
• [2] Heidelberg Pharma AG. (7/13/22). "Press Release: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate (ad hoc)". Ladenburg....
• [3] MediLink Therapeutics (Suzhou) Co., Ltd.. (3/14/22). "Press Release: MediLink Therapeutics Closes US$70 Million Series B Financing". Suzhou....
• [4] Heidelberg Pharma AG. (2/28/22). "Press Release: Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment". Ladenburg....
• [5] ADC Therapeutics S.A.. (1/18/22). "Press Release: ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize Zynlonta(loncastuximab tesirine-lpyl) in Japan". Lausanne....
• [6] Sotio Biotech a.s.. (11/16/21). "Press Release: Sotio Expands Its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences". Prague....
• [7] Synaffix B.V.. (7/22/21). "Press Release: Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies". Amsterdam....
• [8] Iksuda Therapeutics Ltd.. (6/7/21). "Press Release: Iksuda Therapeutics Closes $47 Million Financing Round". Newcastle....
• [9] ADC Therapeutics S.A.. (4/6/21). "Press Release: Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer". Boston, MA, Shanghai & Lausanne....
• [10] Pyxis Oncology, Inc.. (3/30/21). "Press Release: Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.